Biogen Inc. (BIIB)

Market Cap	26.92B +28.9%
Revenue (ttm)	9.89B +2.2%
Net Income	1.29B -20.8%
EPS	8.79 -21.4%
Shares Out	146.76M
PE Ratio	20.87
Forward PE	11.68
Dividend	n/a
Ex-Dividend Date	n/a

Volume	768,650
Open	182.18
Previous Close	182.31
Day's Range	181.68 - 185.45
52-Week Range	110.04 - 202.41
Beta	0.14
Analysts	Buy
Price Target	195.00 (+6.32%)
Earnings Date	Apr 30, 2026

About BIIB

Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar refe...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• IPO Date: Sep 16, 1991
• Employees: 7,500
• Stock Exchange: NASDAQ
• Ticker Symbol: BIIB
• Website: https://www.biogen.com

Financial Performance

In 2025, Biogen's revenue was $9.89 billion, an increase of 2.22% compared to the previous year's $9.68 billion. Earnings were $1.29 billion, a decrease of -20.79%.

Analyst Summary

According to 27 analysts, the average rating for BIIB stock is "Buy." The 12-month stock price target is $195.0, which is an increase of 6.32% from the latest price.

Price Target

$195.0

(6.32% upside)

Analyst Consensus: Buy